Rani Therapeutics' Oral RT-114 Tops 150% Bioavailability
Rani Therapeutics (Nasdaq: RANI) reported Q2 2026 results and updates on RT-114. In Phase 1a, oral RT-114 via the RaniPill Capsule showed bioavailability >150% vs matched subcutaneous PG-102, with similar half-life and no serious adverse events. Rani dosed an expansion cohort, plans Phase 1b repeat-dose obesity study by end-2026, and completed a $20m registered direct offering. Cash was $53.4m at June 30, 2026; Q2 contract revenue was $1.7m and net loss $8.4m.
How this was made
The 30-second read
Why it matters
Traders can frame this as a platform validation and pipeline expansion catalyst, but the investable decision is whether to price in continued clinical progress toward Phase 1b repeat-dose data expected in 2027.
Market read
New quantified PK/bioavailability result plus first dosing in the RT-114 Phase 1a expansion cohort can drive near-term sentiment, while the longer-dated Phase 1b repeat-dose timeline keeps the story risk-weighted.
What to watch
The article also flags rising G&A and ongoing net losses, and the $20M registered direct offering can cap upside if dilution concerns dominate into future clinical milestones.
Background
Rani Therapeutics is a clinical-stage biotech focused on oral delivery of biologics using the RaniPill Capsule platform; RT-114 is being compared against subcutaneous PG-102 in Phase 1a.
Ticker impact
Rani reported Phase 1a RT-114 oral bioavailability over 150% versus matched subcutaneous PG-102 and dosed the expansion cohort.
Likely bullish bias for RANI into follow-on Phase 1a expansion updates, with volatility around clinical readouts and funding optics.
The article discloses new clinical progress (expansion cohort dosing) plus a quantified bioavailability result, alongside a $20M registered direct offering and cash runway through 2027.
Market effects
Reinforces investor appetite for oral biologics delivery platforms and GLP-1/GLP-2 class reformulations, but does not change the broader sector fundamentals.
Limited, primarily US small-cap biotech sentiment and clinical-risk appetite.
Moderate via PegBio collaboration and ProGen-linked comparator (PG-102), but no direct cross-border regulatory or commercial milestone disclosed.
Counterpoint
Bioavailability outperformance does not guarantee efficacy or tolerability in repeat-dose obesity patients; Phase 1a is healthy-volunteer PK with limited clinical signal.
Key entities
- companyRani Therapeutics Holdings, Inc.
Nasdaq-listed clinical-stage oral biologics company reporting Q2 2026 results and RT-114 Phase 1a progress.
- programRT-114
Orally administered RaniPill Capsule delivering PG-102; Phase 1a shows >150% bioavailability vs matched subcutaneous PG-102.
- comparatorPG-102
GLP-1/GLP-2 dual agonist delivered subcutaneously in the Phase 1a study design.
- collaboration_partnerPegBio Co., Ltd.
Rani collaboration partner for oral obesity and metabolic candidates using the RaniPill platform.
- executiveNicholas Maestas
Appointed CFO in June 2026.
